Basque researchers have turned to a drug that can reduce mortality from pneumonia caused by COVID-19 disease. The dose of glucocorticoid methylprednisolone can reduce patient mortality and prevent intubation. It is the result of a study carried out by the Hospital de Cruces, Biocruces Bizkaia, the University of the Basque Country and the biomedical research center CIBERESP.

As reported by EiTB, the study has been published by the scientific journal Plos One and is available on the Internet. According to the specifications, after three days of collection of high doses of methylprednisolone, patients have evolved positively.

This hormone, which helps regulate carbohydrate metabolism, helps to reduce the risk of mortality and prevent intubation. Thus, fewer cases of severe diseases would be admitted to the ICU.